what they said (Hover the mouse cursor over underlined words for more info)

WASHINGTON - Two new treatments doubled the life expectancy of people afflicted with advanced cases of the very common cancer of the kidney, said studies published this week in the United States.

The two medicines belong to a new breed of auspicious cancer treatments that inhibit angiogenesis, the development of blood vessels that feed tumours.

The studies appeared in the Jan. 11 edition of the New England Journal of Medicine...

The original article can be found at: www.canada.com/edmontonjournal/news/bodyandhealth/story.html?id=ea7a27d4-9d12-4d3a-9b08-5887918e8e2f

how did it rate? (more information)

what we said (Hover the mouse cursor over underlined words for more info)

Sunitinib and sorafenib which belong to a new class of agents that are being studied in patients with advanced cancer of the kidney. It appears that these agents do, on average, increase the life span by 3-6 months, but unfortunately, the article provides no information on side effects, cost, or availability of these agents - information clearly required to help consumers make an informed decision.

public forum

voice your opinion in the forum

• All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
• If you provide your email address it will not be displayed to the general public.
• Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
• Required fields are marked with an asterisk (*).